These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37935319)

  • 21. Mesenchymal stromal cell exosome-enhanced regulatory T-cell production through an antigen-presenting cell-mediated pathway.
    Zhang B; Yeo RWY; Lai RC; Sim EWK; Chin KC; Lim SK
    Cytotherapy; 2018 May; 20(5):687-696. PubMed ID: 29622483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T Cell and Cytokine Dynamics in the Blood of Patients after Hematopoietic Stem Cell Transplantation and Multipotent Mesenchymal Stromal Cell Administration.
    Petinati N; Davydova Y; Nikiforova K; Bigildeev A; Belyavsky A; Arapidi G; Drize N; Kuzmina L; Parovichnikova E; Savchenko V
    Transplant Cell Ther; 2023 Feb; 29(2):109.e1-109.e10. PubMed ID: 36372356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduction of Graft-versus-Host-Disease in NOD.Cg-Prkdc
    Hansen M; Stahl L; Heider A; Hilger N; Sack U; Kirschner A; Cross M; Fricke S
    Transplant Cell Ther; 2021 Aug; 27(8):658.e1-658.e10. PubMed ID: 33964513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mesenchymal stromal cells as prophylaxis for graft-versus-host disease in haplo-identical hematopoietic stem cell transplantation recipients with severe aplastic anemia?-a systematic review and meta-analysis.
    Li R; Tu J; Zhao J; Pan H; Fang L; Shi J
    Stem Cell Res Ther; 2021 Feb; 12(1):106. PubMed ID: 33541414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Ressarch Advances of Prevantive and Therapeatic Effect of Mesenchymal Stromal Cells on Graft-Versus-Host Disease--Review].
    Wang L; Ma DX; Liu SF; Gao CJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):283-287. PubMed ID: 30738484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of safety and efficacy of allogeneic adipose tissue-derived mesenchymal stem cells in pediatric bronchiolitis obliterans syndrome (BoS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
    Mohseni R; Mahdavi Sharif P; Behfar M; Modaresi MR; Shirzadi R; Mardani M; Jafari L; Jafari F; Nikfetrat Z; Hamidieh AA
    Stem Cell Res Ther; 2023 Sep; 14(1):256. PubMed ID: 37726865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Highlighting the interaction between immunomodulatory properties of mesenchymal stem cells and signaling pathways contribute to Graft Versus Host Disease management.
    Mirfakhraie R; Ardakani MT; Hajifathali A; Karami S; Moshari MR; Hassani M; Firouz SM; Roshandel E
    Transpl Immunol; 2022 Apr; 71():101524. PubMed ID: 34990789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved NK Cell Recovery Following Use of PTCy or Treg Expanded Donors in Experimental MHC-Matched Allogeneic HSCT.
    Wolf D; Barreras H; Copsel SN; Komanduri KV; Levy RB
    Transplant Cell Ther; 2022 Jun; 28(6):303.e1-303.e7. PubMed ID: 35302008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Role of NK Cells and Their Exosomes in Graft Versus Host Disease and Graft Versus Leukemia.
    Zafarani A; Taghavi-Farahabadi M; Razizadeh MH; Amirzargar MR; Mansouri M; Mahmoudi M
    Stem Cell Rev Rep; 2023 Jan; 19(1):26-45. PubMed ID: 35994137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mesenchymal Stromal Cells for Treating Steroid-Resistant Acute and Chronic Graft Versus Host Disease: A Multicenter Compassionate Use Experience.
    Macías-Sánchez MDM; Morata-Tarifa C; Cuende N; Cardesa-Gil A; Cuesta-Casas MÁ; Pascual-Cascon MJ; Pascual A; Martín-Calvo C; Jurado M; Perez-Simón JA; Espigado I; Garzón López S; Carmona Sánchez G; Mata-Alcázar-Caballero R; Sánchez-Pernaute R
    Stem Cells Transl Med; 2022 Apr; 11(4):343-355. PubMed ID: 35348788
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mesenchymal Stem Cell Derived Extracellular Vesicles: A Role in Hematopoietic Transplantation?
    De Luca L; Trino S; Laurenzana I; Lamorte D; Caivano A; Del Vecchio L; Musto P
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28486431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation.
    Ueha S; Yokochi S; Ishiwata Y; Kosugi-Kanaya M; Shono Y; Shibayama S; Ito S; Matsushima K
    Cancer Sci; 2017 Oct; 108(10):1967-1973. PubMed ID: 28787768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Unique Immunomodulatory Properties of MSC-Derived Exosomes in Organ Transplantation.
    Zheng Q; Zhang S; Guo WZ; Li XK
    Front Immunol; 2021; 12():659621. PubMed ID: 33889158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current status of clinical trials assessing mesenchymal stem cell therapy for graft versus host disease: a systematic review.
    Li Y; Hao J; Hu Z; Yang YG; Zhou Q; Sun L; Wu J
    Stem Cell Res Ther; 2022 Mar; 13(1):93. PubMed ID: 35246235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decreased Soluble Human Leukocyte Antigen E Levels in Patients After Allogeneic Hematopoietic Stem Cell Transplantation Are Associated With Severe Acute and Extended Chronic Graft-versus-Host Disease and Inferior Overall Survival.
    Kordelas L; Schwich E; Lindemann M; Heinemann FM; Buttkereit U; Horn PA; Beelen DW; Rebmann V
    Front Immunol; 2019; 10():3027. PubMed ID: 31998310
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in the treatment of graft-versus-host disease with immunomodulatory cells.
    Yu Q; Wang H; Zhang L; Wei W
    Int Immunopharmacol; 2021 Mar; 92():107349. PubMed ID: 33486323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First-line allogeneic hematopoietic stem cell transplantation of HLA-matched sibling donors compared with first-line ciclosporin and/or antithymocyte or antilymphocyte globulin for acquired severe aplastic anemia.
    Peinemann F; Bartel C; Grouven U
    Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD006407. PubMed ID: 23881658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. International Society for Cell & Gene Therapy Stem Cell Engineering Committee: Cellular therapies for the treatment of graft-versus-host-disease after hematopoietic stem cell transplant.
    Garcia-Rosa M; Abraham A; Bertaina A; Bhoopalan SV; Bonfim C; Cohen S; DeZern A; Louis C; Oved J; Pavel-Dinu M; Purtill D; Ruggeri A; Russell A; Sharma A; Wynn R; Boelens JJ; Prockop S
    Cytotherapy; 2023 Jun; 25(6):578-589. PubMed ID: 36941149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Graft-Versus-Host Disease Amelioration by Human Bone Marrow Mesenchymal Stromal/Stem Cell-Derived Extracellular Vesicles Is Associated with Peripheral Preservation of Naive T Cell Populations.
    Fujii S; Miura Y; Fujishiro A; Shindo T; Shimazu Y; Hirai H; Tahara H; Takaori-Kondo A; Ichinohe T; Maekawa T
    Stem Cells; 2018 Mar; 36(3):434-445. PubMed ID: 29239062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.